ApoPharma – Pantothenate Kinase-Associated Neurodegeneration

Access Program Information

Patients with pantothenate kinase-associated neurodegeneration (PKAN) who have completed the
ApoPharma-sponsored study TIRCON2012V1-EXT and who wish to continue to take deferiprone will
be offered the opportunity to receive it on a compassionate basis. Patients will be followed
locally by their own neurologist or other appropriate specialist.